Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 148-3,700 MBq/mL (4-100 mCi/mL) per vial at end of synthesis
Breast Cancer PET Imaging
Indicated for use with positron-emission tomography (PET) imaging to detect estrogen receptor positive (ER+) lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer
222 MBq (6 mCi), range of 111-222 MBq (3-6 mCi), administered as a single IV injection of ≤10 mL over 1-2 minutes
Dosing Considerations
Before administration
- Assess for drug interactions (eg, drugs targeting estrogen receptors)
- Assess pregnancy status in females of reproductive potential
Limitations of use
- Use tissue biopsy to confirm recurrence of breast cancer and to verify ER status by pathology
- Fluoroestradiol F 18 is not useful for imaging other receptors (eg, human epidermal growth factor receptor 2 [HER2], progesterone receptor [PR])
Not indicated
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (0)
Adverse Effects
<1%
General disorders: Injection-site pain
Neurological and gastrointestinal disorders: Dysgeusia
Warnings
Contraindications
None
Cautions
Radiation risks
- Diagnostic radiopharmaceuticals expose patients to radiation
- Radiation exposure is associated with a dose-dependent increased risk of cancer
- Ensure safe drug handling and patient preparation procedures to protect patients and healthcare providers from unintentional radiation exposure
Misdiagnosis risks
-
Inadequate tumor characterization and other ER+ pathology
- Breast cancer may be heterogeneous within patients and across time
- Fluoroestradiol F 18 images ER and is not useful for imaging other receptors (eg, HER2, PR)
- Uptake is not specific for breast cancer and may occur in a variety of ER+ tumors that arise outside of the breast, including uterus and ovaries
- Do not use in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer
-
False-negative scan
- A negative scan does not rule out ER+ breast cancer
- Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative scan
Drug interaction overview
- Certain classes of systemic endocrine therapies, including ER modulators and ER down-regulators, block ER, reduce the uptake of fluoroestradiol F 18, and may reduce detection of ER+ lesions after administration
- Drugs from these classes (eg, tamoxifen, fulvestrant) may block ER for up to 8-28 weeks, respectively
- Do not delay indicated therapy in order to administer fluoroestradiol F 18
- Administer fluoroestradiol F 18 before starting systemic endocrine therapies that block ER
Pregnancy & Lactation
Pregnancy
All radiopharmaceuticals have potential to cause fetal harm depending on fetal stage of development and the magnitude of radiation dose
Advise pregnant females of the potential risks of fetal exposure to radiation from administration
There are no available data on use during pregnancy
No animal reproduction studies have been conducted
Lactation
There are no data on the presence of fluoroestradiol F 18 in human milk, or its effects on breastfed infants or milk production
Lactation studies have not been conducted in animals
Advise breastfeeding females to avoid breastfeeding for 4 hr after administration
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Fluoroestradiol F 18 binds estrogen receptor (ER)
The following binding affinity: Kd = 0.13 ± 0.02 nM, Bmax = 1901 ± 89 fmol/mg, and IC50 = 0.085 nM, was determined in an ER+ human breast cancer cell line (MCF7)
Distribution
Protein bound: 95%
Distributes primarily to hepatobiliary system, and also to small and large intestines, heart wall, blood, kidney, uterus, and bladder
Metabolism
Metabolized in liver; 20 minutes after injection, ~20% of circulating radioactivity in plasma is in the form of nonmetabolized fluoroestradiol F 18; at 2 hr after injection, circulating fluoroestradiol F 18 levels are <5% of peak concentration
Elimination
Excretion: Biliary and urinary
Administration
IV Preparation
Use aseptic technique and radiation shielding when withdrawing and administering
Visually inspect solution; do not use if it contains particulate matter or is cloudy or discolored (fluoroestradiol F 18 is a clear, colorless solution)
May be diluted with 0.9% NaCl
Assay dose in a suitable dose calibrator before administration
Patient preparation
- Instruct patients to drink water to ensure adequate hydration before administration and continue drinking and voiding frequently during the first hours following administration to reduce radiation exposure
Image acquisition
- Position patient supine with arms above the head, if possible
- Recommended start time for image acquisition is 80 minutes after IV administration
- Scan duration adapted from range of 20-30 minutes and imaging start times adapted within range of 20-80 minutes may be customized according to equipment used and patient and tumor characteristics for optimal image quality
Image interpretation
- Uptake of fluoroestradiol F 18 depends on ER density and function in tumors and physiologic tissue, including liver, ovary, and uterus
- Base detection of ER+ tumors on comparison with tissue background outside of organs with high physiologic uptake and regions with high activity due to hepatobiliary and urinary excretion
- See radiation dosimetry in prescribing information for specific tissues
Radiation safety
- Fluoroestradiol F 18 is a radioactive drug; only authorized persons qualified by training and experience should receive, use, or administer
- Handle with appropriate safety measures to minimize radiation exposure during administration
- Use waterproof gloves and effective radiation shielding, including syringe shields, when preparing and handling
IV Administration
Administer IV over 1-2 minutes
Follow injection with IV flush of 0.9% NaCl
Dispose of any unused drug in compliance with radiopharmaceutical regulations
Storage
Store at 20-25ºC (68-77ºF)
Store upright in original container with radiation shielding
Expiration date and time are provided on the container label
Use within 10 hr from the time of the end of synthesis
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.